https://www.selleckchem.com/pr....oducts/idasanutlin-r
001) in the active group compared with the placebo group (time × group interaction; P less then 0.001). The change in UMSARS scores did not differ between the active and placebo groups. However, the active group showed better alterations in MoCA scores with nominal significance (P less then 0.001) and tendency for better alterations in MMSE scores (P = 0.09) than the placebo group. Our data demonstrated that IMP treatment was generally safe and well-tolerated in patients with MSA. A further trial with a long-term follow-up i
Like
Comment
Share
